期刊文献+

骨唾液蛋白和基质金属蛋白酶-9在风湿性心脏病钙化瓣膜中的表达及意义 被引量:1

The expression and significance of bone sialoprotein and matrix metalloproteinase-9 in calcified valves of patients with rheumatic heart disease
原文传递
导出
摘要 目的观察骨唾液蛋白(BSP)和基质金属蛋白酶.9(MMP-9)在风湿性心脏病(风心病)钙化瓣膜中的表达情况。方法将手术切除的二尖瓣瓣膜(共150枚)按病史分为风心病组(120枚)和非风心病组(30枚),采用sP法进行免疫组织化学染色,观察并比较两组BSP和MMP-9的:羡达情况。结果风心病组BSP和MMP-9阳性表达率分别为91.7%(11-120)和90.8%(109/120),显著高于非风心病组的23.3%(7/30)和20.0%(6/30),差异均有统计学意义(P〈0.01)。结论风心病瓣膜BSP和MMP-9高表达,风心病瓣膜的钙化与MMP-9所引起的细胞外基质降解和重塑以及BSP所诱导的成骨样骨形成密切相关。 Objective To observe the expression of bone sialoprotein (BSP) and matrix metalloproteinase-9 (MMP-9) in calcified valves of patients with rheumatic heart disease. Methods A total of 150 mitral valves which were resected by surgery were divided into rheumatic group ( 120 valves ) and non- rheumatic group (30 valves). Immunohistochemical staining was taken by SP method and the expressions of BSP and MMP-9 in two groups were observed and compared. Results The positive expressions of BSP aJld MMP-9 in rheumatic group were 91.7%(110/120) and 90.8%(109/120) ,respectively,which were significantly higher than those in non-rheumatic group [23.3%(7/30) and 20.0%(6/30) ](P〈 0.01 ). Conclusions The expressions of both BSP and MMP-9 are higher in the valves of patients with rheumatic heart disease. The calcification of rheumatic mitral valves is closely related with the degradation and remodeling of extracellular matrix caused by MMP-9, and osteoblast-hke bone formation induced by BSP.
出处 《中国医师进修杂志》 2012年第20期13-15,共3页 Chinese Journal of Postgraduates of Medicine
关键词 唾液蛋白类 基质金属蛋白酶9 风湿性心脏病 Sialoglycoproteins Matrix metalloproteinase 9 Rheumatic heart disease
  • 相关文献

参考文献6

  • 1[1]张宝仁,朱家麟.人造心脏瓣膜与瓣膜置换术[M].第2版.北京:人民卫生出版社,2000:291-293.
  • 2Karadag A, Ogbureke KU, Fed~rko NS, et al. Bone sialoprotein, matrix metaUoproteinase 2, and alpha (v) beta3 integrin in osteotropic cancer cell invasion. J Nail Cancer Inst, 2004, 96 (12) :956-965.
  • 3Mohsin SK, Zhang M, Clark GM, et al. Maspin expression in invasive breast cancer: associaton with other prognostic factors. J Pathol, 2003, 199(4) :432-435.
  • 4Jian B, Jones PL, Li Q, et al. Matrix metalloproteinase-2 is associated with tenascin-C in calcific aortic stenosis. Am J Pathol, 2001,159 (1) : 321-327.
  • 5Kaden JJ, Vocke DC, Fischer CS, et al. Expression and activity of matrix metalloproteinase-2 in c~tlcific aortic stenosis. Z Kardiol, 2004, 93(2) : 124-130.
  • 6Fondard O, Detaint D, lun~ B, et al. Extracellular matrix remodelling in human aortic valve disease: the role of matrix metalloproteinases and their tissue inhibitors. Eur Heart J, 2005,26(13) : 1333-1341.

共引文献4

同被引文献14

  • 1Authors/Task Force Members, McMurray J J, Adamopoulos S,et al. ESC Guidelines for the diagnosis and treatment of acute and chron-ic heart failure 2012:The Task Force for the Diagnosis and Treat- ment of Acute and Chronic Heart Failure 2012 of the European So- ciety of Cardiology. Developed in collaboration with the Heart Fail- ure Association(HFA) of the ESC [ J ]. Eur J Heart Fail, 2012,14 (8) :803-869.
  • 2Maeder MT, Rickli H, Pfisterer ME, et al. Incidence, clinical pre- dictors, and prognostic impact of worsening renal function in eld- erly patients with chronic heart failure on intensive medical thera- py[J]. Am Heart J,2012,163(3) :407-414.
  • 3Ahmed A, Fonarow GC, Zhang Y, et al. Renin-angiotensin inhibi- tion in systolic heart failure and chronic kidney disease[ J]. Am J Med,2012,125 (4) :399-410.
  • 4Cullington D, Goode KM, Clark AL, et al. Heart rate achieved or beta-blocker dose in patients with chronic heart failure:which is the better target[ J]. Eur J Heart Fail,2012,14 (7) :737-747.
  • 5Zeng Q, Jiang S. Update in diagnosis and therapy of coexistent chronic obstructive pulmonary disease and chronic heart failure [ J]. J Thorac Dis,2012,4(3 ) :310-315.
  • 6Kramer F, Mihing H. Novel biomarkers in human terminal heart failure and under mechanical circulatory support [ J ]. Biomarkers, 2011,16( Suppl 1 ) :S31-41.
  • 7Mehta PA, MeDonagh S, Phillips J, et al. Angiotensin receptor blocker therapy for heart failure patients :is combination treatment a feasible prospect[ J]. Clin Cardiol,2009,32(9) :513-518.
  • 8Fares H, Lavie C J, Ventura HO. Vasodilating versus first-genera- tion β-blockers for cardiovascular protection [ J ]. Postgtad Med, 2012,124(2) :7-15.
  • 9Kato TS, Chokshi A, Singh P, et al. Markers of extracellular matrix turnover and the development of fight ventricular failure after ven- tricular assist device implantation in patients with advanced heart failure[ J]. J Heart Lung Transplant,2012,31 (1) :37-45.
  • 10冯耀光,朱德胜,王元星,贺大璞,韦兵,聂军,龙超众,莫靓.血管紧张素转换酶抑制剂与β-受体阻滞剂对心瓣膜置换术后心脏结构及功能的影响[J].中国胸心血管外科临床杂志,2011,18(4):377-379. 被引量:4

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部